Table 3.
Base case results
| Inputs in model | US model PemC | US model PCB | ∆ US PCB—PemCa | Japan model PemC (in US$) | Japan model PCB (in US$) | ∆ Japan PCB—PemCa |
|---|---|---|---|---|---|---|
| Drug acquisition costs | ||||||
| Induction | $17,380 | $21,937 | $4557 | $12,141 | $18,402 | $6261 |
| Maintenance | $19,576 | $23,830 | $4254 | $12,461 | $17,053 | $4592 |
| Premedication | $15 | $15 | $0 | $83 | $175 | $93 |
| Subsequent therapy | $4990 | $8810 | $3820 | $3217 | $5948 | $2730 |
| First-line therapy (induction + maintenance) | $1956 | $2389 | $433 | $528 | $524 | $4 |
| Subsequent therapy | $407 | $529 | $122 | $125 | $166 | ($41) |
| Toxicity | $8970 | $9700 | $730 | $99 | $157 | $58 |
| G-CSF use | $2128 | $3472 | $1344 | $2765 | $4512 | $1747 |
| ESA use | $2047 | $510 | ($1537) | $634 | $189 | ($445) |
| Transfusions | $141 | $55 | ($86) | $38 | $15 | ($24) |
| Total | $57,609 | $71,248 | $13,639 | $32,090 | $47,140 | $15,049 |
ESA Erythropoiesis-stimulating agent, G-CSF Growth colony stimulating factor, PCB Induction bevacizumab plus paclitaxel plus carboplatin followed by single-agent bevacizumab, PemC Induction pemetrexed plus carboplatin followed by single-agent pemetrexed
aDifference in 2013 $US; parentheses indicate negative values where PemC is more expensive; overall differences vary due to rounding